 Graybug Vision Inc NASDAQ: GRAY has provided full-data analysis from the 12-month treatment Phase of its Phase 2b ALTISSIMO trial evaluating GB-102 to treat wet age-related macular degeneration wet AMD. GB-102 is a proprietary formulation of sunitinib malate injected twice a year intravitreally. 